We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sourcebio International Plc | SBI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 115.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 115.00 |
| Top Posts |
|---|
Posted at 17/12/2022 21:55 by finkie And a further question what happens to investors buying stock and holding at 100p do they still own a part of source bio as a private company but able to own at a lower price? |
Posted at 17/12/2022 21:52 by finkie Hi so I bought some at 115p 2 weeks ago with view of holding outside an isa and letting them run the business outside of the stock market as a private company.Two questions when do they fully de list and my investment I assume just gets carried forward as a private company investor is that correct? Thanks |
Posted at 05/4/2022 17:46 by base7 Positive Investor Meets & my question was responded to first -ie regarding rationale for cash purchase .Vendors have been in a close period ,until today ,have substantial amounts of cash & if they are as committed as our Leader suggests they should be keen to buy shares ,either in Market or from Mills or Fumagalli |
Posted at 05/4/2022 10:31 by base7 Encouraging but curious as to why we paid 100% cash (& no SBI equity)for LD & that wasn’t addressed in this mornings Proactive interview but hopefully it will be raised in this afternoons Investor Meets as the question must be asked |
Posted at 29/3/2022 23:34 by base7 Let's hope it's not Lecoque by name & nature then.Our major investors must have discussed the deal in detail & be happy with it -& they are not fools.A couple of mill in shares ,at least,would have given them some skin & hard to imagine how they could have negotiated for cash only without Lecoque not appreciating how poorly that reflects on their view of our prospects? |
Posted at 29/3/2022 17:58 by base7 My concern is that since the substantial reduction in PCR/LF testing exhausting that wonderful cash cow 9 for now ) the cash was burning a hole in their pockets & consequently overpaid for a relatively new company giving a fantastic capital return to the initial investors, who all appear to be taking cash rather than our cheap ( allegedly) paper.Poor that who ever negotiated this deal could not encourage a reasonable amount of equity in SBI -especially as their senior team all appear relatively/very young & therefore you would hope committed to the project.I will await Results on 5/4 & IM before deciding but bailing is one distinct possibility for my insignificant holding here . |
Posted at 07/3/2022 12:30 by km18 ...from last month...Company overview: Sourcebio International is a laboratory services provider for clients in the clinical, life science research and biopharma industries. As a result, human tissue testing services, genomics services and histopathology reporting services are intuitively covered and offered to biotechnological companies and pharmaceuticals. These enriching initiatives and highly stimulating laboratory services were efficiently reflected on the firm’s financial performance, as full year results will be substantially ahead of market expectations. Consequently, it implies that revenue is expected to reach £92.4m, resulting in an 82% hike with respect to the previous revenue of £50.7m in 2020. This plausible corporate news suggested that EBITDA leapt to £24.1m and thereby soared 70%, in relation to the EBITDA of £14.2m derived in 2020. Furthermore, the firm’s net cash position was simultaneously ahead of market expectations and stood at £33.3m, higher than the £8.4m net cash generated in 2020. From a valuation perspective, Sourcebio International derived an attractive P/E ratio of 22.9x, which is lower than the healthcare sector P/E ratio of 26.3x, signifying that the Sourcebio International is undervalued with respect to the healthcare sector, hence it is cheaply available for investors to purchase the stock, since it is expected to surge in value. Brief Analysis: EBITDA of £24.1m. P/E ratio of 22.9x, lower than the healthcare sector benchmark Revenue of £92.4m, higher than last year. Net cash of £33.3m, substantially above previous year... ...from WealthOracleAM |
Posted at 11/1/2022 15:06 by ptolemy Last year we had a Trading Update on 18 January and an Investor presentation on13 January. Hopefully, an update is due.... |
Posted at 21/9/2021 08:30 by smithless See the US will require a test NAAT/PCR 3 days before travel, so not all bad news. Think the directors have to start looking beyond PCR and start talking mid to long term strategy, deploying cash and how it can move beyond just being a testing lab and create USP in its products (personal DNA for example). The CEO needs to get a good story for investors to believe in. |
Posted at 20/9/2021 07:30 by charlieej Underlying business is worth approx. The current market cap. Add cash Bringen built up through COVID and the business looks undervalued anyway without the COVID testing. I personally think that the market was already pricing in a reduction in COVID testing as SBI price didn't get hit with other CIVID testers when the news was announced last week. Not to say it won't put some investors off. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
